C反应蛋白和降钙素原指导高危新生儿预防性应用抗生素的效果、安全性和经济性分析

doi:10.12092/j.issn.1009-2501.2019.05.013

摘要/Abstract

摘要：

目的:评价应用C反应蛋白（C reaction protein，CRP）和降钙素原（procalcitonin，PCT）指导高危新生儿预防性应用抗生素的效果、安全性和经济性。方法:选取2015年7月至2017年1月慈溪市妇幼保健院收治的高危新生儿124例作为研究对象，随机数表法分为对照组（62例）和实验组（62例），对照组患儿均给予预防性应用抗生素治疗，实验组根据CRP和PCT选择性应用抗生素。比较两组患儿的细菌培养阳性率、脓毒症发生率以及不良反应发生率。结果:两组患儿的CRP和PCT水平和阳性率间均不存在统计学差异（t/χ2=0.299，-0.461，0.292，0.544，0.186，P=0.766，0.646，0.589，0.461，0.666）。两组患儿治疗前后的菌培养阳性率间均不存在统计学差异（χ2=0.040，0.287，P=0.842，0.592）；两组治疗后的菌培养阳性率均明显低于治疗前（χ2=47.825，40.367，P=0.000，0.000）；两组患儿脓毒症的发生率分别为12.90%和14.52%，差异无统计学意义（χ2=0.068，P=0.794）。实验组的NICU治疗和住院时间、机械通气时间以及治疗费用均显著低于对照组（t=2.904，2.729，2.152，5.337，P=0.004，0.007，0.033，0.000），两组的机械通气率间无统计学差异（χ2=0.372，P=0.542）。对照组患儿不良反应发生率为19.35%，明显高于实验组的6.46%（χ2=4.593，P=0.032）。结论:应用CRP和PCT指导高危新生儿预防性应用抗生素的效果与普遍性应用相似，可以明显减少治疗时间和治疗费用，明显降低治疗相关不良反应。

关键词: 高危新生儿, 抗生素, C反应蛋白, 降钙素原, 安全性

Abstract:

AIM: To evaluate the efficacy, safety and economics of C reaction protein (CRP) and procalcitonin (PCT) in the prevention of the use of antibiotics in high-risk newborns. METHODS:One hundred and twenty-four cases of high risk neonates treated in our hospital from July 2015 to January 2018 were selected as the research subjects and were divided into the control group (62 cases) and the experimental group (62 cases) by random digital tables. The children in the control group were treated with prophylactic antibiotic treatment. The experimental group was treated with selective antibiotics according to the level of CRP and PCT. The positive rate of bacterial culture, the incidence of sepsis and the incidence of adverse reactions were compared between the two groups. RESULTS:There was no statistical difference between the levels of CRP and PCT and the positive rate in the two groups (t/χ2=0.299, -0.461, 0.292, 0.544, 0.186, P=0.766, 0.646, 0.589, 0.461, 0.666). There was no statistical difference in the positive rates of bacteria culture before and after treatment in the two groups (χ2=0.040, 0.287, P=0.842, 0.592), and the positive rate of bacteria culture in the two groups was significantly lower than that before treatment (χ2=47.825, 40.367, P=0.000, 0.000), and the incidence of sepsis in two groups was 12.90% and 14.52%, respectively, which have no statistical significance (χ2=0.068, P=0.794). The NICU treatment in the experimental group was significantly lower than that in the control group (t=2.904, 2.729, 2.152, 5.337, P=0.004, 0.007, 0.033, 0.000), and there was no statistical difference between the two groups (χ2=0.372, P=0.542). The incidence of adverse reactions in the control group was 19.35%, which was significantly higher than that in the experimental group (6.46%, χ2=4.593, P=0.032). CONCLUSION:The effect of preventive use of antibiotics under the guidance of CRP and PCT in high-risk newborns show similar efficay of universal application, which can significantly reduce treatment time and treatment costs, obviously reduce treatment-related adverse reactions and improve the short-term prognosis.

Key words: high-risk newborns, antibiotics, C-reactive protein, procalcitonin, safety

中图分类号:

R722.13+1

华旭丹，解红艺，余淑芳. C反应蛋白和降钙素原指导高危新生儿预防性应用抗生素的效果、安全性和经济性分析[J]. 中国临床药理学与治疗学, 2019, 24(5): 561-566.

HUA Xudan, XIE Hongyi, YU Shufang. Analysis of the efficacy, safety and economics of prophylactic antibiotics in high-risk neonates guided by C reaction protein and procalcitonin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 561-566.

参考文献

［1］Huynh BT, Padget M, Garin B, et al. Bacterial neonatal sepsis and antibiotic resistance in low-income countries［J］. Lancet, 2016,387(10018):533-534.
［2］Berardi A, Tzialla C, Travan L, et al. Secondary prevention of early-onset sepsis: a less invasive Italian approach for managing neonates at risk［J］. Ital J Pediatr, 2018,44(1):73.
［3］Cantey JB, Wozniak PS, Pruszynski JE, et al. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study［J］. Lancet Infect Dis, 2016,16(10):1178-1184.
［4］Mukherjee A, Davidson L, Anguvaa L, et al. NICE neonatal early onset sepsis guidance: greater consistency, but more investigations, and greater length of stay［J］. Arch Dis Child Fetal Neonatal Ed, 2015,100(3):F248-F249.
［5］Escobar GJ, Puopolo KM, Wi S, et al. Stratification of risk of early-onset sepsis in newborns ≥ 34 weeks' gestation［J］. Pediatrics, 2014,133(1):30-36.
［6］《中华医学会中华儿科杂志》编辑委员会. 新生儿败血症诊疗方案［J］. 中华儿科杂志, 2003,41(12):897-899.
［7］Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury［J］. Am J Kidney Dis, 2013,61(5):649-672.
［8］Puopolo KM, Benitz WE, Zaoutis TE. Management of neonates born at ≥35 0/7 weeks' gestation with suspected or proven early-onset bacterial sepsis［J］. Pediatrics, 2018,142(6):e20182896.
［9］Korpela K, Zijlmans MA, Kuitunen M, et al. Childhood BMI in relation to microbiota in infancy and lifetime antibiotic use［J］. Microbiome, 2017,5(1):26.
［10］Schulfer A, Blaser MJ. Risks of antibiotic exposures early in life on the developing microbiome［J］. PLoS Pathog, 2015,11(7):e1004903.
［11］韩愈, 杨心宇, 陈晓璐, 等. 地诺前列酮栓联合头孢呋辛治疗足月胎膜早破的临床疗效及对白细胞介素6、C反应蛋白的影响［J］. 中国临床药理学与治疗学, 2018,23(6):700-703.
［12］王剑, 张文. 探讨血清PCT浓度、SVRI、SOFA评分在脓毒症患者中的相关性及临床意义［J］. 中国临床药理学与治疗学, 2017,22(4):443-447.
［13］Nakstad B. The diagnostic utility of procalcitonin, interleukin-6 and interleukin-8, and hyaluronic acid in the Norwegian consensus definition for early-onset neonatal sepsis (EONS)［J］. Infect Drug Resist, 2018,11:359-368.
［14］Mohsen AH, Kamel BA. Predictive values for procalcitonin in the diagnosis of neonatal sepsis［J］. Electron Physician, 2015,7(4):1190-1195.
［15］吕菊红, 马红茹, 李文君. PCT和CRP测定在新生儿败血症早期诊断中的价值［J］. 中国妇幼健康研究, 2012,23(4):463-465.
［16］朱丽坤, 温洁新. Hs-CRP与PCT在新生儿败血症早期诊断及病情评估中的应用［J］. 实用医学杂志, 2016,32(6):1002-1003.
［17］常淑婷, 李贵南, 吴运芹, 等. 降钙素原及超敏C反应蛋白在新生儿败血症诊断中的价值［J］. 中国小儿急救医学, 2013,20(4):411-413.
［18］Wang J, Johnson T, Sahin L, et al. Evaluation of the safety of drugs and biological products used during lactation: workshop summary［J］. Clin Pharmacol Ther, 2017,101(6):736-744.
［19］Campbell SC, Spigarelli MG, Courter J, et al. Metabolic and toxicological considerations for sepsis drug treatments［J］. Expert Opin Drug Metab Toxicol, 2013,9(1):79-89.
［20］Ting JY, Synnes A, Roberts A, et al. Association between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants without culture-proven sepsis or necrotizing enterocolitis［J］. JAMA Pediatr, 2016,170(12):1181-1187.
［21］Stocker M, van Herk W, El HS, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)［J］. Lancet, 2017,390(10097):871-881.

[1]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[2]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 黄凯. 经口吸入制剂在中国健康受试者生物等效性试验中的安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(10): 1131-1138.
[3]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[4]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[5]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.
[6]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[7]	杨海静，郁继诚，王晶晶，李南洋，吴菊芳，张海，薛涛，戴卫国，丁天凌，曹国英. 生物制剂I期临床试验中的风险管控：案例分享[J]. 中国临床药理学与治疗学, 2020, 25(1): 44-48.
[8]	王思捷，张峻，李骞，黄桦，王晶晶，周琼，姚勤. 艾司西酞普兰用于妊娠期抑郁的安全性研究探讨[J]. 中国临床药理学与治疗学, 2019, 24(9): 1070-1074.
[9]	王海莉，巩天晓，周士霞，梅家转，张中冕. 甲磺酸阿帕替尼三线治疗晚期非小细胞肺癌患者的疗效及安全性分析[J]. 中国临床药理学与治疗学, 2019, 24(5): 567-572.
[10]	康辉，雍小兰，胡婷婷，储碧心，王蓝天. 国产拉科酰胺片的药动学及安全性评价[J]. 中国临床药理学与治疗学, 2019, 24(2): 192-197.
[11]	杨科，李峻岭，杜斌，田中秋，景秀娟. 白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索性临床研究[J]. 中国临床药理学与治疗学, 2019, 24(11): 1281-1286.
[12]	李文书，董淮富. 血清降钙素原在细菌性脑膜炎中的价值[J]. 中国临床药理学与治疗学, 2019, 24(11): 1315-1320.
[13]	赵全凤，符佩姝，马欢，赵粟裕，郭代红，唐敏. 伏立康唑所致肝功能损害的主动监测研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 43-48.
[14]	彭朋，元唯安，胡薏慧，汤洁，蒋健. 药物临床试验不良事件监管问题分析[J]. 中国临床药理学与治疗学, 2018, 23(1): 78-82.
[15]	方潇碧，周琴双，廖志苏. 复方倍他米松注射液联合埃索美拉唑治疗喉接触性肉芽肿的临床研究[J]. 中国临床药理学与治疗学, 2017, 22(6): 680-683.